Earnings ·
Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, a 6.6% increase over the prior year, with…
JNJJohnson & Johnson
Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, a 6.6% increase over the prior year, with adjusted EPS of $2.90. The company raised its full-year 2026 guidance, increasing estimated reported sales to a midpoint of $101.1 billion and adjusted EPS guidance by $0.13 to a midpoint of $11.68. Key growth drivers included the Innovative Medicine segment, specifically oncology products like Darzalex and Carvykti. The company also announced a new supply chain restructuring program in the Innovative Medicine segment with estimated costs between $650 million and $750 million to be completed by 2029. The company operates in the healthcare industry, specializing in innovative medicine and medical technology.